BERLIN, NIMES, France and RICHMOND, Calif., June 22 /PRNewswire/ -- BRAHMS Aktiengesellschaft, a global diagnostics company, Cezanne, and Lumiphore Inc., a biotechnology leader in new proprietary fluorescent metal-lanthanide technology for use in high-value applications, announced that they have signed an agreement on incorporation of Lumiphore's Lumi4(R)-Tb complexes in BRAHMS diagnostic tests.
Under the agreement, BRAHMS together with its subsidiary Cezanne, developer and manufacturer of KRYPTOR automated diagnostic solutions, has the non-exclusive rights to incorporate Lumi4(R) technology into current and future diagnostic tests and the exclusive rights to use the technology in diagnostic tests for Down's Syndrome including Trisomy 21, 13 and 18, Triploidy, Translocation, and Mosaicism.
"Lumiphore's goal is to bring the benefits of lanthanide-based homogenous assays to the diagnostic markets, from central labs to point-of-care applications. Detection sensitivity and simplicity of use as well as material cost reductions in reagent use, labor, and reader platforms are all benefits of Lumiphore's new reporter technology," said Steve Blose Lumiphore's Chief Business Officer.
"Using Lumi4(R)-Tb in the reader technology of our diagnostic tests will provide multiple benefits for BRAHMS. Thus we will take Lumi4(R)-Tb into consideration for the development of future analysis systems, both in laboratories and point-of-care-formats," said Ansgar Schmitt, BRAHMS' Vice President Business Development.
BRAHMS' KRYPTOR analysis systems can currently perform various analyses in random-access operations using TRACE (Time Resolved Amplified Cryptate Emission) technology, based on Forster resonance energy transfer (FRET). - FRET uses two fluorophores as a donor and an acceptor. The energy transfer between these two occurs when in nanometer scale proximity, which allows accurate measurement of molecul
|SOURCE Lumiphore, Inc.; Cezanne, SAS; BRAHMS Aktiengesellschaft|
Copyright©2009 PR Newswire.
All rights reserved